The long-term basic safety and nutritional great things about liprotamase was also evaluated in a second Phase 3 study in patients with persistent pancreatitis or pancreatectomy.. Alnara to announce Stage 3 study outcomes of liprotamase for treating cystic fibrosis in the 23rd NACFC Alnara Pharmaceuticals, Inc., a pharmaceutical business developing novel, nonsystemic orally-delivered protein therapeutics for the treatment of metabolic diseases, announced today that results from a landmark, international Phase 3 research of the long-term safety and nutritional great things about liprotamase for the treatment of pancreatic insufficiency in sufferers with cystic fibrosis will be shown at the 23rd Annual UNITED STATES Cystic Fibrosis Meeting being held October 15-17, 2009 in Minneapolis, Minnesota.The results of our study provide information that may be used to track or predict disease, as well as new diet-based therapeutic strategies, he added. The analysis included 90 children with Crohn’s disease and 26 healthy kids. The youngsters with Crohn’s disease received either diet-based or anti-inflammatory treatments. Non-e of the treatments fully restored the total amount of gut microbes compared to that of a wholesome child, the researchers said. After starting a therapeutic formula-based diet, the gut microbiota look also less similar compared to that of a wholesome child, suggesting that one does not have to give back again the healthy microbiota to possess a therapeutic effect necessarily.